Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fundamental Home Items Each Animal person Needs06.06.2024 - 2Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay17.10.2023
- 310 times the sky amazed us in 202522.12.2025
- 4Instructions to Utilize Your Brain science Certification to Work on Corporate Culture17.10.2023
- 56 US States for Fly Fishing01.01.1
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- 7 Methods for further developing Rest Quality
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Europe pledges over €15bn for clean energy for Africa
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- Get To Be familiar with The Historical backdrop Of Western Medication
- The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
